WINNER! Best Seed Stage Company 2019

WINNER! Best of Oregon 2019

Sparrow Pharmaceuticals is developing novel, proprietary new standards of care for Cushing's syndrome.

Cushing's syndrome is caused by a steroid excess, either of the natural steroid cortisol due a tumor (endogenous Cushing's) or long-term use of a steroid drug such as prednisone (exogenous Cushing's).

Our pipeline is led by a late-stage (with clinical proof-of-concept) product to treat endogenous Cushing's and a second Phase 2 product to treat exogenous Cushing's.

Sparrow Pharmaceuticals appreciates institutional support from both Chicago and Portland.